Estriol ( DrugBank: Estriol )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	3
227	Osler disease	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03774407 (ClinicalTrials.gov)	June 20, 2019	5/12/2018	Vaginal Estriol in Multiple Sclerosis	Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis;Neurogenic Bladder	Drug: vaginal estriol	Texas Tech University Health Sciences Center	NULL	Completed	40 Years	65 Years	Female	21	Phase 2/Phase 3	United States
2	NCT01466114 (ClinicalTrials.gov)	October 2011	31/10/2011	Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition	A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.	Relapsing-remitting Multiple Sclerosis;Secondary-progressive Multiple Sclerosis;Primary-progressive Multiple Sclerosis	Drug: estriol;Other: Placebo;Drug: Norethindrone;Other: Progestin Placebo	University of California, Los Angeles	NULL	Recruiting	18 Years	55 Years	Female	64	Phase 2	United States
3	NCT00451204 (ClinicalTrials.gov)	March 2007	22/3/2007	A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)	A Combination Trial of Copaxone Plus Estriol in RRMS	Relapsing Remitting Multiple Sclerosis	Drug: Estriol;Drug: Placebo;Drug: Copaxone	University of California, Los Angeles	Washington University School of Medicine;University of Texas Southwestern Medical Center;Ohio State University;University of Medicine and Dentistry of New Jersey;University of Chicago;University of Utah;Johns Hopkins University;University of Kansas Medical Center;University of Minnesota, MN;Mayo Clinic;University of Colorado, Aurora;University of New Mexico;University of Pennsylvania;Dartmouth-Hitchcock Medical Center;National Multiple Sclerosis Society;National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)	Completed	18 Years	50 Years	Female	158	Phase 2	United States;Canada

227. Osler disease

---

Clinical trials : 54 /  Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01408030 (ClinicalTrials.gov)	August 2011	1/8/2011	North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	North American Study of Epistaxis in HHT (NOSE)	Telangiectasia, Hereditary Hemorrhagic;Epistaxis	Drug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic Acid	James Gossage	HHT Foundation International	Completed	18 Years	N/A	All	123	Phase 2	United States